Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services REDWOOD CITY, Calif., Nov.

Positions the Company as a new leader in providing solutions that bridge the gap between cellular electrophysiology and advanced analysis

ST. LOUIS, March 15, 2023 /PRNewswire/ — Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled

VENLO, The Netherlands & SAN DIEGO–(BUSINESS WIRE)– QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of

Madison, WI USA, January 5, 2023–/BusinessWire/ — Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify

MADISON, WI, USA, December 13, 2022 — Nimble Therapeutics Inc., a leading peptide therapeutics company, today announced they have achieved

Madison, Wisconsin, November 30th, 2022 – Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough,

October 24, 2022 | For Immediate Release Former Healthcare Research Analyst and Investment Banker Expands Firm’s Operational Depth and Sector

San Francisco, June 30, 2022 – Telegraph Hill Partners (THP), a venture capital and growth equity firm dedicated to building

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to